AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 112 min read$BDX

Garrison Michael David sold $167K of BDX

Garrison Michael David (EVP & Pres Med.Essntl&BioPharm) sold 1,100 shares of BECTON DICKINSON & CO (BDX) at $151.48 ($0.17M total) on 2026-06-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Garrison Michael David
Published Jun 11, 2026, 9:21 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 11, 2026, 9:24 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$BDX
Neutral
medium confidence
Mentioned
$BDX
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BDXNeutralLow
01

Why it matters

The newest fact is the disclosed sale size, price ($151.48/share), and that it was executed under a pre-arranged 10b5-1 plan.

02

Market read

Provides a fresh insider-selling datapoint, but the 10b5-1 designation reduces interpretive weight.

03

What to watch

Traders may over-weight insider sales; without accompanying buys, guidance changes, or operational news, the signal is usually weak.

Relevance 3/10Novelty 6/10Timing: Filed 2026-06-11; sale executed 2026-06-10

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for Becton Dickinson & Co.

Company-level read

Ticker impact

$BDXNeutralMedium confidence
Context

Bdcton Dickinson insider Form 4 shows EVP Michael David Garrison sold 1,100 shares on 2026-06-10 under a 10b5-1 plan.

Expected impact

Likely minimal immediate price impact; any reaction would be sentiment-driven rather than fundamental.

Evidence & confidence

The filing is a primary SEC Form 4 disclosure, but it specifies a pre-arranged 10b5-1 plan and is a single, moderate-size sale relative to a large-cap issuer.

Market effects

Sector

No direct sector read-across; this is company-specific insider transaction data.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is explicitly under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • issuer
    Becton Dickinson & Co

    BDX, the company whose shares were sold by an executive under a 10b5-1 plan.

  • insider
    Garrison Michael David

    EVP & Pres, Med. Essential & BioPharm; sold 1,100 shares on 2026-06-10.

Read at source← All news

Related articles

AUG 8
$REPLMed

This Week at FDA: Inspection reorg, acting CBER chief eyes IND reforms, and more

FDA updates cover inspection reorganization plans, proposed IND reforms for early-stage biologics research, and accelerated approval of Replimune’s Tudriqev (vusolimogene oderparepvec-wtpg) with Bristol Myers Squibb’s Opdivo for melanoma after PD-1 regimens. Other items include FDA workshops, Seegene EUA for an assay, and multiple drug/device recalls.

raps.org7 min
AUG 6
$BDXMed

Becton, Dickinson Boosts FY26 Adj. EPS Outlook - Update

Becton, Dickinson and Co. (BDX) reported third-quarter results and raised its FY2026 adjusted EPS outlook to $12.62 to $12.72 per share, from $12.52 to $12.72. The company kept its revenue growth view, expecting low single-digit plus growth and low single-digit constant-currency growth. Shares were about $172.00 premarket.

rttnews.com2 min
AUG 6
$BDXMedAI 8/10

BD Reports Third Quarter Fiscal 2026 Financial Results

BD (NYSE:BDX) reported fiscal 2026 third-quarter results ended June 30, 2026. Revenue rose to $5.0 billion, up 5.4% reported and 4.4% on an FX-neutral basis. GAAP and adjusted diluted EPS from continuing operations were $1.64 and $3.23. Year-to-date cash from continuing operations increased 33.3% to $2.1 billion, and free cash flow rose 44.6% to $1.7 billion. BD updated full-year guidance, expecting revenue growth toward the high end and raised the adjusted EPS midpoint.

prnewswire.com6 min